Trials / Completed
CompletedNCT00763503
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
Pharmacokinetic and Pharmacodynamic Study of CD 2027 3µg/g Oily Spray Applied Twice Daily for 3 Weeks Under Conditions of Maximized Use in Adults With Plaque-type Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and Treatment period (Day 1/ Baseline, Day 15 and Day 22).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD 2027 | 3µg/g Oily Spray |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2008-12-01
- Completion
- 2009-02-01
- First posted
- 2008-10-01
- Last updated
- 2021-02-18
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00763503. Inclusion in this directory is not an endorsement.